KalVista Pharmaceuticals (KALV) Common Equity (2016 - 2024)
Historic Common Equity for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $164.4 million.
- KalVista Pharmaceuticals' Common Equity changed N/A to $164.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $164.4 million, marking a year-over-year change of. This contributed to the annual value of $206.6 million for FY2024, which is N/A changed from last year.
- Per KalVista Pharmaceuticals' latest filing, its Common Equity stood at $164.4 million for Q4 2024.
- Over the past 5 years, KalVista Pharmaceuticals' Common Equity peaked at $206.6 million during Q2 2024, and registered a low of $58.6 million during Q1 2021.
- Over the past 4 years, KalVista Pharmaceuticals' median Common Equity value was $102.1 million (recorded in 2020), while the average stood at $116.0 million.
- As far as peak fluctuations go, KalVista Pharmaceuticals' Common Equity tumbled by 3474.43% in 2021, and later surged by 2401.69% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Common Equity stood at $65.0 million in 2020, then fell by 9.87% to $58.6 million in 2021, then skyrocketed by 95.42% to $114.4 million in 2023, then skyrocketed by 43.61% to $164.4 million in 2024.
- Its Common Equity stands at $164.4 million for Q4 2024, versus $134.0 million for Q4 2024 and $172.8 million for Q3 2024.